Arterial Spin-Labeling and DSC Perfusion Metrics Improve Agreement in Neuroradiologists’ Clinical Interpretations of Posttreatment High-Grade Glioma Surveillance MR Imaging—An Institutional Experience

References

1. 1.↵
   2. Wen PY,
   3. Macdonald DR,
   4. Reardon DA, et al

   . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

   Abstract/FREE Full Text
2. 2.↵
   2. Weinberg BD,
   3. Gore A,
   4. Shu HG, et al

   . Management-based structured reporting of posttreatment glioma response with the Brain Tumor Reporting and Data System. J Am Coll Radiology 2018;15:767–71 doi:10.1016/j.jacr.2018.01.022 pmid:29503151

   CrossRefPubMed
3. 3.↵
   2. Barajas RF Jr.,
   3. Chang JS,
   4. Segal MR, et al

   . Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253:486–96 doi:10.1148/radiol.2532090007 pmid:19789240

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Hu LS,
   3. Baxter LC,
   4. Smith KA, et al

   . Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552–58 doi:10.3174/ajnr.A1377 pmid:19056837

   Abstract/FREE Full Text
5. 5.↵
   2. Prager AJ,
   3. Martinez N,
   4. Beal K, et al

   . Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 2015;36:877–85 doi:10.3174/ajnr.A4218 pmid:25593202

   Abstract/FREE Full Text
6. 6.↵
   2. Ozsunar Y,
   3. Mullins ME,
   4. Kwong K, et al

   . Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. Acad Radiol 2010;17:282–90 doi:10.1016/j.acra.2009.10.024 pmid:20060750

   CrossRefPubMed
7. 7.↵
   2. Liu Y,
   3. Chen G,
   4. Tang H, et al

   . Systematic review and meta-analysis of arterial spin-labeling imaging to distinguish between glioma recurrence and post-treatment radiation effect. Ann Palliat Med 2021;10:12488–97 doi:10.21037/apm-21-3319 pmid:35016424

   CrossRefPubMed
8. 8.↵
   2. Nguyen TB,
   3. Zakhari N,
   4. Velasco Sandoval S, et al

   . Diagnostic accuracy of arterial spin-labeling, dynamic contrast-enhanced, and DSC perfusion imaging in the diagnosis of recurrent high-grade gliomas: a prospective study. AJNR Am J Neuroradiol 2023;44:134–42 doi:10.3174/ajnr.A7771 pmid:36702501

   Abstract/FREE Full Text
9. 9.↵
   2. Iv M,
   3. Liu X,
   4. Lavezo J, et al

   . Perfusion MRI-based fractional tumor burden differentiates between tumor and treatment effect in recurrent glioblastomas and informs clinical decision-making. AJNR Am J Neuroradiol 2019;40:1649–57 doi:10.3174/ajnr.A6211 pmid:31515215

   Abstract/FREE Full Text
10. 10.↵
    2. Geer CP,
    3. Simonds J,
    4. Anvery A, et al

    . Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study. AJNR Am J Neuroradiol 2012;33:556–62 doi:10.3174/ajnr.A2811 pmid:22116105

    Abstract/FREE Full Text
11. 11.↵
    2. Hu LS,
    3. Baxter LC,
    4. Pinnaduwage DS, et al

    . Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010;31:40–48 doi:10.3174/ajnr.A1787 pmid:19749223

    Abstract/FREE Full Text
12. 12.↵
    2. Schmainda KM,
    3. Prah MA,
    4. Rand SD, et al

    . Multisite concordance of DSC-MRI analysis for brain tumors: results of a National Cancer Institute Quantitative Imaging Network collaborative project. AJNR Am J Neuroradiol 2018;39:1008–16 doi:10.3174/ajnr.A5675 pmid:29794239

    Abstract/FREE Full Text
13. 13.↵
    2. Schmainda KM,
    3. Prah MA,
    4. Hu LS, et al

    . Moving toward a consensus DSC-MRI protocol: validation of a low-flip angle single-dose option as a reference standard for brain tumors. AJNR Am J Neuroradiol 2019;40:626–33 doi:10.3174/ajnr.A6015 pmid:30923088

    Abstract/FREE Full Text
14. 14.↵
    2. Prah MA,
    3. Al-Gizawiy MM,
    4. Mueller WM, et al

    . Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics. J Neurooncol 2018;136:13–21 doi:10.1007/s11060-017-2617-3 pmid:28900832

    CrossRefPubMed
15. 15.↵
    2. Hu LS,
    3. Kelm Z,
    4. Korfiatis P, et al

    . Impact of software modeling on the accuracy of perfusion MRI in glioma. AJNR Am J Neuroradiol 2015;36:2242–49 doi:10.3174/ajnr.A4451 pmid:26359151

    Abstract/FREE Full Text
16. 16.↵
    2. Hu LS,
    3. Eschbacher JM,
    4. Heiserman JE, et al

    . Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol 2012;14:919–30 doi:10.1093/neuonc/nos112 pmid:22561797

    CrossRefPubMed
17. 17.↵
    2. Connelly JM,
    3. Prah MA,
    4. Santos-Pinheiro F, et al

    . Magnetic resonance imaging mapping of brain tumor burden: clinical implications for neurosurgical management: case report. Neurosurg Open 2021;2:okab029 doi:10.1093/neuopn/okab029 pmid:34661110

    CrossRefPubMed
18. 18.↵
    2. Maiter A,
    3. Butteriss D,
    4. English P, et al

    . Assessing the diagnostic accuracy and interobserver agreement of MRI perfusion in differentiating disease progression and pseudoprogression following treatment for glioblastoma in a tertiary UK centre. Clin Radiol 2022;77:e568–75 doi:10.1016/j.crad.2022.04.011 pmid:35636976

    CrossRefPubMed
19. 19.↵
    2. Kerkhof M,
    3. Hagenbeek RE,
    4. van der Kallen BF, et al

    . Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme. Eur J Neurol 2016;23:1528–33 doi:10.1111/ene.13070 pmid:27424939

    CrossRefPubMed
20. 20.↵
    2. Yang Y,
    3. Yang Y,
    4. Wu X, et al

    . Adding DSC PWI and DWI to BT-RADS can help identify postoperative recurrence in patients with high-grade gliomas. J Neurooncol 2020;146:363–71 doi:10.1007/s11060-019-03387-6 pmid:31902040

    CrossRefPubMed